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1. Introduction 
We previously identified a MOZ-TIF2 (transcriptional intermediary factor 2) fusion gene 
from a young female patient with acute myeloid leukemia (AML) (Liang et al., 1998). MOZ 
related chromosome translocations include MOZ-CREB-binding protein (MOZ-CBP, 
t(8;16)(p11;p13)), MOZ-P300(t(8;22)(p11;q13)), MOZ-TIF2(inv(8)(p11q13), and MOZ-
NCOA3(t(8;20)(p11;q13)) (Esteyries et al., 2008; Troke et al., 2006). In an animal model, the 
MOZ-TIF2 fusion product successfully induced the occurrence of AML (Deguchi et al., 
2003). Though the mechanisms for leukemogenesis of this fusion protein are poorly 
understood, analysis of functional domains in the MOZ-TIF2 fusion protein discloses at least 
two distinct functional domains: 1) the MYST domain containing the C2HC nucleosome 
recognition motif and the histone acetyltransferase motif in the MOZ portion and 2) the CID 
domain containing two CBP binding motifs in the TIF2 portion. Together these domains 
were responsible for AML in mice caused by injecting bone marrow cells transduced with 
retrovirus containing the MOZ-TIF2 fusion gene. Furthermore, MOZ-TIF2 conferred the 
properties of leukemic stem cells (Huntly et al., 2004). The MOZ-TIF2 transduced mouse 
common myeloid progenitors and granulocyte-monocyte progenitors exhibited the ability to 
serially replated in vitro. The cell line derived from transduced progenitors could induce 
AML in mice. Interestingly, the C543G mutation in C2HC nucleosome recognition motif or 
in the CBP binding motif (LXXLL) blocked the self-renewal function of MOZ-TIF2 
transduced progenitors. More recently, a study using PU.1 deficient mice demonstrated that 
the interaction between MOZ-TIF2 and PU.1 promoted the expression of macrophage 
colony–stimulating factor receptor (CSF1R). Cells with high expression of CSF1R are 
potential leukemia initiating cells(Aikawa et al., 2010). Models suggesting that aberrant 
transcription by the interaction between MOZ fusion proteins and transcription factors, 
AML1, p53, PU1, or NF-kB have been well reviewed(Katsumoto et al., 2008).  
MOZ as a fusion partner of MOZ-TIF2 is a member of MYST domain family 
(MOZ/YBF2/SAS2/TIP60) and acetylates histones H2A, H3 and H4 as a histone 
acetyltransferase (HAT) (Champagne et al., 2001; Kitabayashi et al., 2001). MOZ is a cofactor 
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in the regulation of transcriptional activation of several target genes important to 
hematopoiesis, such as Runx1 and PU.1 (Bristow and Shore, 2003; Katsumoto et al., 2006; 
Kitabayashi et al., 2001). MOZ-/- mice died at embryonic day 15 and exhibited a significant 
decrease of mature erythrocytes (Katsumoto et al., 2006). The histone acetyltransferase 
activity of MOZ is required to maintain normal functions of hematopoietic stem cells (HSC) 
(Perez-Campo et al., 2009). Mice with mutation at HAT or MYST domain (G657E) showed a 
decreased population of HSC in fetal liver. The lineage-committed hematopoietic 
progenitors from fetal liver cells with HAT-/- mutant had reduced colony formation ability.  
In our attempt to find proteins that interact with the fusion protein by using as bait a 
construct of the MOZ N-terminal fragment, encoding the first 759 amino acids of MOZ-TIF2 
fusion gene and containing the H15, PHD, and MYST domains, we were able to isolate two 
proteins, the p150 subunit or subunit A of the human chromatin assembly factor-1 
(p150/CAF-1A) and the human anti-silencing function protein 1 homolog B (ASF1B). Both 
of these proteins were verified to interact with the MOZ partner of MOZ-TIF2 fusion in the 
yeast two-hybrid system. The interaction has been further characterized by co-
immunoprecipitation, protein pull-down assays, and co-localization by 
immunohistochemistry. The differences in the interactions of CAF-1A and ASF1B with wild 
type MOZ and the MOZ-TIF2 fusion proteins may contribute to leukemogenesis. 
2.Materials and methods 
2.1 The sources of cDNAs and plasmid constructions  
The cDNA for MOZ was kindly provided by Julian Borrow (Center for Cancer Research, 
Massachusetts Institute of Technology, MA) and TIF2 was a kind gift from Hinrich 
Gronemeyer (Institut de Genetique et de Biologie Moleculaire et Cellulaire, France). A full 
length MOZ-TIF2 fusion was created by inserting a RT-PCR fragment crossing the MOZ–
TIF2 fusion site into the Hind3 site of wild type of human MOZ and the Sac1 site of human 
TIF2 in pBluescript KS phagemid vector (pBlueKS). The cDNAs for CAF-1A and ASF1B 
were screened and rescued from Human Bone Marrow MATCHMAKER cDNA Library (BD 
Biosciences Clontech Palo Alto, CA) by the yeast two-hybrid system using the N-terminal 
fragment of the MOZ-TIF2 fusion as bait. The cDNAs from the positive clones, which were 
in the pACT2 vector, were switched into the pBlueKS vector at EcoRI and XhoI sites and 
sequenced with a T7 primer. The resulting sequences were identified in the NCBI GenBank 
as the subunit A (p150) of human chromatin assembly factor-1 (GenBank accession No. NM-
005483) and human anti-silencing function protein 1 homolog B (GenBank accession No. 
AF279307). The full length of both cDNAs was confirmed by DNA sequencing with gene 
specific primers. For the visualization of the expression and localization in mammalian cells, 
the full length of MOZ, MOZ-TIF2, TIF2, CAF-1A, and ASF1B were subcloned in frame into 
the C-terminal fluorescent protein Vector, pEGFP or pDsRed2 (BD Biosciences Clontech, 
Palo Alto, CA) to generate fluorescent fusion proteins. For studies of protein-protein 
interaction in vitro, glutathione S-transferase (GST) fusions of MOZ fragments were 
constructed in the pGEX vector (Amersham Biosciences, Piscataway, NJ). Briefly, the full 
length MOZ cDNA was digested with Asp718/BgI2 from pBlueKS-MOZ and was ligated 
into the pET-30a (EMD Biosciences, Inc. Novagen Madison, WI) plasmid at Asp718/BamH1 
site to create the pET-30a-MOZ construct. A PET-30a-MOZ-1/759 (amino acids 1 to 759) 
www.intechopen.com
MOZ-TIF2 Fusion Protein Binds to Histone  
Chaperon Proteins CAF-1A and ASF1B Through Its MOZ Portion 5 
construct was generated by removing a Hind3/Hind3 fragment from pET-30a-MOZ and 
then re-ligating. This fragment was then switched from pET-30a vector to pGEX-4T at a 
Not1/Xho1 site to construct the pGEX-4T-MOZ-1/759. The pGEX-4T-MOZ-1/313 (amino 
acids 1 to 313) containing H15 and the PHD domain was generated by the deletion of a 1515 
base pair fragment from pGEX-4T-MOZ-1/759 with Hind3 /Blin1 followed by re-ligation.  
The pGEX-6P-MOZ-488/703 plasmid was constructed by inserting an EcoRV to Eag1 
fragment of MOZ (amino acids 488 to 703) containing the C2HC motif and acetyl-CoA 
binding region to pGEX-6P-2 vector at Sma1/Eag1 sites. To create pET-30a-CAF-1A, the 
pBlueKS-CAF-1A was first digested with XhoI and then digested partially with NcoI. A 3.1 
kb fragment was recovered by agarose electrophoresis and was ligated to NcoI/XhoI sites of 
pET-30a vector. The pET-30c-ASF1B was constructed by inserting the 1 kilobase 
EcoR1/Hind3 fragment of pBLueKS-ASF1B into the pET-30c vector at EcoR1 /Hind3 sites.  
2.2 Yeast two-hybrid screen  
pGBD-MOZ-MYST, a bait plasmid with a fusion of the N-terminal fragment of MOZ-TIF2 
to the GAL4 DNA binding domain was constructed by inserting a 2.3 kb fragment 
encoding amino acids 1 to 759 of human MOZ to BamH1/blunted Bgl 2 sites in the pGBD-
C3 vector (James et al., 1996). The bait plasmid was transformed into the yeast host PJ69-
2A and mated with pre-transformed Human Bone Marrow MATCHMAKER cDNA 
Library according to the manufacturer’s instruction. The mating culture was plated on 25 
x 150 mm triple dropout (TDO) dishes (SD/-His/-Leu/-Trp) and 25 x 150 mm quadruple 
dropout (QDO) dishes (SD/-Ade/-His/-Leu/-Trp). After incubation for 7 and 14 days, 
the more than 100 colonies which grew on TDO and QDO dishes were picked for re-
screening on SD/-His, SD/-Ade/ and QDO dishes. A total of five colonies were grown 
from the second screening. The plasmids from each colony were rescued and transformed 
into KC8 cells. All of the plasmids were re-transformed into the yeast host PJ69-2A and  
Y187; no auto-transcription activation of any reporter was seen. The pVA3.1 plasmids 
containing either the murine p53 in PJ69-2A or the PTD1-1 with SV 40 large T antigen in  
Y187 were used as controls for DNA binding domain and activation domain fusions. The 
plasmids from positive clones were subjected to restriction enzyme mapping which 
showed two potential interacting genes which were subsequently sequenced and 
identified with the NCBI database.  
2.3 Co-localization of MOZ or MOZ-TIF2 and CAF-1A or ASF1B 
To identify the co-localization of expressed fluorescent fusion proteins, HEK293 cells were 
grown in DMEM (Mediatech Cellgro, VA) containing 10% fetal bovine serum (FBS) and co-
transfected by pEGFP-MOZ or pEGFP-MOZ-TIF2 and pDsRed2-CAF-1A or pDsRed2-
ASF1B with Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Briefly, cells were grown on a 
coverslip in a 12-well plate a day before the transfection in the antibiotic-free medium to 
reach 80-90% confluence on the next day. 1.6 µg of DNA in 100 µl of Opti-MEM I Reduced 
Serum Medium (Invitrogen, Carlsbad, CA) was mixed with 100 µl of diluted Lipofectamine 
2000 reagent. After incubation for 20 min. at room temperature, the DNA-Lipofectamine 
2000 complex was added to the cells and 48 hours later, subcellular location of expressed 
fluorescent fusion proteins was examined with a Zeiss fluorescent microscope equipped 
with Axiocam system and by a laser scanning confocal microscope (Bio-Rad Laser Scanning 
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System Radiance 2000/Nikon Eclipse TE300 microscope). To examine the subcellelular 
localization of endogenously expressed MOZ and CAF-1A, HEK293 and Hela cells were 
fixed with 4% paraformaldehyde and then blocked with Ultra V block (Lab Vision Co.CA). 
For some experiments pre-extraction with 0.3%Triton-X100 was conducted. The fixed cells 
were then incubated with antibody against MOZ (N-19, Santa Cruz Biotechnology, Inc, 
Santa Cruz, CA) at 1:100 and /or antibody against CAF-1A (a kind gift from Dr. Bruce 
Stillman, Cold Spring Harbor, NY). In some experiments, the antibody against CAF-1A and 
ASF1B were purchased from Cell Signaling Technology, MA. The immunofluorescence of 
MOZ, CAF-1A, or ASF1B was observed as described above for examination of expressed 
EGFP fusion proteins.  
2.4 Co-immunoprecipitation and immunoblotting 
HEK293 cells were transfected with EGFP fusions of MOZ, MOZ-TIF2, or TIF2. After 48 
hours of transfection, whole cell lysates was prepared with plastic individual homogenizers 
in the lysis buffer [50 mM NaCL, 5mM KCL, 1mM EDTA, 20 mM HEPES, pH 7.6, 10% 
glycerol, 0.5% NP-40, and protease inhibitor cocktails (Roche Applied Science, IN)]. 
Immunoprecipitation was conducted with an antibody against EGFP (BD Biosciences, Palo 
Alto, CA). Briefly, 2 µg of anti-EGFP antibody and protein A/G-agarose (Santa Cruz 
Biotechnology, Santa Cruz, CA) were added to 0.8 ml of cell lysate (about 500 µg protein) 
and incubated overnight at 4°C with rotation. The precipitate was collected by 
centrifugation, extensively washed, subjected to SDS-PAGE, transferred onto Hybond-ECL 
nitrocellulose membrane (Amersham Pharmacia Biotech, Piscataway, NJ), and examined by 
immunoblotting with the antibody against CAF-1A.  
2.5 Expression of GST fusion proteins and GST pull down assay 
E. coli BL21-CodonPlus®(DE3)-RIL Competent Cells (Stratagene, La Jolla, CA) were 
transformed with pGEX vectors containing cDNA fragments MOZ-1/759, MOZ-1/313, or 
MOZ-488/703 and grown in LB medium. To induce protein expression isopropyl β-D-
thiogalactopyranoside (IPTG) was added at final concentration of 1mM when the A600 of the 
cultures reached 0.6 to 0.8. After three more hours of growth at 28° C, cells were collected by 
centrifugation and resuspended in cold PBS containing 1% Triton X-100 and protease 
inhibitor cocktail and kept on ice for 30 minutes. Cell lysates were prepared by 
ultrasonication followed by centrifugation at 15,000 rpm for 30 minutes at 4˚C. GST fusion 
proteins were purified with the GST Purification Module (Amersham Pharmacia Biotech, 
Piscataway, NJ). Purified GST fusion proteins were examined with SDS-PAGE followed by 
Coomassie Blue staining. To perform GST pull down affinity assays [35S]Methionine-labeled 
proteins were first produced with Single Tube Protein® System 3 or EcoProTM T7 system 
(EMD Biosciences, Inc. Novagen, Madison, WI) from pET 30 vectors carrying full length of 
CAF-1A or ASF1B. The binding reaction was conducted with 5µl of in vitro-translated 
protein and 3-5 µg of GST alone or GST fusion protein attached to Sepharose 4B beads in 200 
µl binding buffer (50mM Tris-HCI , pH 8.0, 100 mM NaCl, 0.3 mM DTT, 10mM MgCl2, 10% 
glycerol, 0.1% NP40). The reaction was conducted at 4 °C for 1 hour followed by five washes 
with 400 µl of binding buffer. The final pellet was separated by SDS-PAGE, autoradiography 
performed, and radioactivity detected with a phosphorimager.  
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2.6 In Vitro protein binding assay with S-tagged fusion protein 
The S-tagged fusion of ASF1B was expressed from pET-30c-ASF1B in E. coli BL21-
CodonPlus® (DE3)-RIL cells after induction with 0.8 mM of IPTG and purification with S-
tagged agarose beads. The fusion protein on agarose beads was incubated with 150µl (about 
600 µg of protein) of cell extract from HEK293 cells transfected with pEGFP fusion protein. 
The beads were pelleted, washed, and the “pull-down” proteins examined as described 
above with the anti-EGFP antibody. 
2.7 RNA isolation and microarray analysis 
RNA was isolated from stably transfected U937 cells with TRI Reagent® (Molecular Research 
Center, Inc., Cincinati, OH). The analysis of gene expression profile was conducted on the 
Human Genome U95A Array (Affymetrix, Inc., Santa Clara, CA). The cRNA was 
synthesized from 10µg of total RNA. The hybridization and signal detection was completed 
in the Core Facility at LSUHSC-Shreveport according to the standard Affymetrix protocol. 
The human U95A array represents 12,256 oligonucleotides of known genes or expression 
tags. The expression profile was analyzed with GeneSifter software. In pairwise analysis, the 
quality was set as 0.5 for at least one group in order to minimize the effect of low intensity 
or poor quality spots. Genes with a > 2-fold change and with P<0.05 in a student T-test were 
considered as either significantly up or down regulated genes. To find genes either 
commonly or differentially expressed in the gene list, we set the quality as 1 to obtain 
positive expressed genes in pattern navigation analysis. The analysis results were exported 
for Venn Diagram analysis using the GeneSifter intersector tool.  
3.Results 
3.1 Screening for MOZ interacting proteins by the yeast two-hybrid system 
A MOZ cDNA fragment encoding amino acids 1 to 759 cloned into pGBD was used as the 
bait in the yeast two-hybrid system in which the prey was a human cDNA bone marrow 
library. After a second screening five β-galactosidase positive clones grew on SD/-His 
plates. To eliminate any of these clones as representing false positive clones, plasmid DNA 
from each clone was rescued using KC8 cells and transformed into PJ69-2A cells carrying 
pGDB-MOZ-MYST. The transformants were then selected on five different media: –Trp/ -
Leu, -His, -His+5mM 3-amino-1,2,4-triazole (3-AT), -His+10mM 3-AT, and –Ade and 
interaction with the MOZ fragment was verified in all five of the clones (Figure 1). Clone 3.1 
grew on –His, -His+10mM 3-AT, and –Ade medium indicative of a strong physical 
interaction; the other clones only grew on –His and –His + 5 mM 3-AT, but not on –Ade, 
indicating a weaker interaction. DNA sequencing of the putatively strongly MOZ 
interacting protein demonstrated that the cDNA encoded the full length CAF-1A. The more 
weakly interacting cDNAs represented the entire coding region of ASF1B.  
3.2 Identify the interaction between MOZ and CAF-1A in human cells 
In yeast, the MYST family member Sas2 was found to interact with Cac1, the largest subunit 
of Saccharomyces cerevisiae chromatin assembly factor-I (CAF-1) (Meijsing and Ehrenhofer-
Murray, 2001) but it is not known if the interaction between the homologous proteins in 
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mammalian cells, MOZ and CAF-1A, takes place in human cells and if any interaction 
occurs between the MOZ-TIF2 fusion protein and CAF-1A. To address these areas we 
looked for interactions by co-immunoprecipitation using transfections with the  
 
Fig. 1. Protein interaction between MOZ and CAF-1A or ASF1B in the yeast two-hybrid 
system. The yeast two-hybrid system was used with pretransformed Matchmaker 
libraries as detailed in the Methods. The bait was the fragment encoding amino acids 1 to 
759 of the human MOZ gene in the pGAL 4 DNA-BD vector. In the upper panel controls 
are plated on 5 different selection media: P, positive control diploid with plasmid pDT1-1 
encoding an AD/SV40 large T-antigen fusion protein and pVA3-1 carrying DNA-
BD/murine P53 fusion protein. N, negative control diploid. MOZ, a diploid with GAL4 
DNA-BD+ MOZ fragment of amino acids 1 to 759. E, a diploid with GAL4 DNA-BD 
vector only. In the lower panel the five clones (1.3, 1.4, 3.1, 5.3, and 5.4) that were positive 
after a second screening were plated in duplicate on the same media. Clones 1.3, 1.4, 5.3, 
and 5.4 show an interaction between MOZ and ASF1B; clone 3.1 shows an interaction 
between the MOZ and CAF-1A. Trp, tryptophan, Leu, leucine, His, histidine, Ade, 
adenine, 3-AT, 3-amino-1,2,4,triazole. 
MOZ and MOZ-TIF2 fusion constructs into HEK293 cells which express CAF-1A (Figure 2). 
In these experiments the HEK293 cells were transfected with EGFP fusions of MOZ, MOZ-
TIF2 and TIF2, the expressed fusion proteins precipitated with anti-EGFP antibody and the 
presence of co-precipitated CAF-1A assayed by western blot analysis.  Only with the 
product of the EGFP-MOZ construct was a significant amount of CAF-1A precipitated 
(Figure 2A); a far smaller amount was precipitated with MOZ-TIF2. By comparison to the 
intensity of the CAF-1A band in the input lane, which represents 10% of the amount of 
lysate subjected to immunoprecipitation, approximately 35-40% of the HEK293 cell CAF-1A 
was estimated to be co-precipitated with the transfected MOZ. In contrast, less than 10% of 
the CAF-1A co-precipitated with MOZ-TIF2 (Figure 2A).  The differences in the amount of 
CAF-1A precipitated were not a result of altered expression of CAF-1A or of differences in 
expression levels of the transfectants as the expression of CAF-1A was not affected by any of 
the three transfectants (Figure 2B) and the EGFP-tagged MOZ and MOZ-TIF2 proteins 
showed similar levels of expression, while TIF2 showed a 2-3 fold higher expression than 
MOZ and MOZ-TIF2 (Figure 2C).  
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3.3 The MOZ portion of MOZ-TIF2 fusion interacts physically with CAF-1A through the 
N-terminal of MOZ  
Using the yeast two-hybrid system we have shown that CAF-1A interacted with a MOZ 
fragment extending from amino acids 1 to 759. Within this region are PHD (amino acids 195-
320) and MYST (amino acids 562-750) domains that are potential sites for the interaction 
with (Figure 3A) (Champagne et al., 1999). 
 
Fig. 2. Co-precipitation of CAF-1A (p150) with EGFP-tagged MOZ, MOZ-TIF2, and TIF2. 
The EGFP constructs of MOZ, MOZ-TIF2, and TIF2 were transfected into HEK293 cells. 
Panel A. After 48 hours, whole cell extracts were prepared in lysis buffer and subjected to 
immunoprecipitation with anti-EGFP antibody, followed by SDS-PAGE, and western blot 
analysis with anti-p150 antibodies. The input lane corresponds to 10% of the amount of 
lysate subjected to immunoprecipitation. Lane C2 represents the pEGFP-C2 vector alone and 
MT2 represents MOZ-TIF2. Panel B. The lysates of the various transfectants were subjected 
to SDS-PAGE followed by western blot analysis with anti- p150 antibody to demonstrate the 
expression level of p150 in the transfected cells. Panel C. The same lysates used in Panel B 
were subjected to a western blot analysis with anti-EGFP antibody to demonstrate the 
expression of EGFP-tagged MOZ, MOZ-TIF2 and TIF2. 
To further define the region containing the binding domain, a pull down assay using GST 
fusion proteins was established. First, a GST-tagged MOZ fragment from amino acids 1 to 
759 was used to pull down CAF-1A and to demonstrate that the GST did not interfere with 
the MOZ-CAF-1A interactions shown earlier (Figure 3B).  We then generated two GST-
tagged MOZ fragments, one encompassing amino acids 1-313 (MOZ-1/313) containing the 
H15 and PHD domains and the other from amino acids 488-703 (MOZ-488/703) including 
the C2HC motif and acetyl-CoA binding region (Figure 3 C, left panel). These peptides were 
used with [35S]methionine labeled CAF-1A synthesized in an in vitro translation system and 
interactions detected with a GST pull down assay (Figure 3C). For equivalent amounts of 
fusion peptides more MOZ-1/313 was bound to CAF-1A than MOZ-488/703 (Figure 3C).  
As a percentage of the input radioactivity, MOZ-1/313 pulled down about 30 % of the 
[35S]methionine labeled CAF-1A while MOZ-488/703 pulled down only 14%. Further 
www.intechopen.com
 Protein Interactions 10
analysis of domain interactions showed that strongest binding was seen between MOZ-
1/313 and CAF-1A-176/327 among all peptides (Figure 3D). CAF-1A-176/327 pulled down 
about 328% of [35S]methionine labeled MOZ-1/313 and pulled down only 76% of MOZ-




Fig. 3. The interaction between MOZ fragments and CAF-1A (p150). GST-tagged MOZ 
fragments were expressed and purified with glutathione Sepharose 4B as described in 
Materials and Methods. [35S]-methionine labeled p150 protein was produced from a T7-
driven pET-30 plasmid with an in vitro translation system. A, binding assay was conducted 
with [35S]-methionine labeled p150 and the GST-tagged MOZ fragments. The input lane is 
10% of the [35S] methionine p150 protein added to the binding assay. A, schematic structure 
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of MOZ and MOZ-TIF2. B, interaction between p150 and the MOZ fragment from amino 
acids 1 to 759 using the binding assay as described in the Materials and Methods. C, left 
panel, SDS-PAGE of the purified GST-MOZ-1/313 and GST-MOZ-488/703 peptides to 
demonstrate that the peptides were of the expected molecular weights; right panel, as 
described in Materials and Methods [35S]-methionine labeled p150 synthesized in a cell-free 
translation system was incubated in vitro with equivalent amounts of GST fusions with 
MOZ-1/313 or MOZ-488/703, the resulting complexes isolated by GST-pull down assay, 
and the amount of [35S]-methionine labeled p150 detected by radioautography following 
SDS-PAGE. D, left panel, SDS-PAGE of the purified GST-p150-176/327 and GST-p150-
620/938 fusion peptides; right panel, GST pulldown assays as described in C with [35S]-
methionine labeled MOZ-1/313 (a) and MOZ-488/703(b) peptides. The bottom line 




Fig. 4. ASF1B interacts with MOZ and MOZ-TIF2. Panel A. HEK293 cells were transfected 
with EGFP-MOZ, EGFP-MOZ-TIF2, and EGFP-TIF2 as detailed in the Materials and 
Methods. At 48 hours after transfection cell lysates were incubated with S–tagged ASF1B 
absorbed to S-tag agarose beads and after extensive washing the proteins bound to ASF1B 
were analyzed by SDS-PAGE with subsequent western blot analysis with anti-GFP 
antibody. Lane 1, 10% of input; lane 2, S-tag protein alone; lane 3, S-tagged ASF1B.  
Panel B. GST pull down assays were performed as detailed above incubating GST- ASF1B 
with [35S]-methionine labeled MOZ-1/313 or MOZ-488/703 peptides synthesized in a cell-
free translation system as described in the Material and Methods. 
3.4 Confirmation of ASF1B as an interacting protein of MOZ and MOZ-TIF2 
The yeast two-hybrid system also revealed a cDNA encoding another protein, ASF1B, 
which interacted with the MOZ-1/759 fragment. To verify the interaction between MOZ 
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and ASF1B and to examine if the MOZ-TIF2 fusion protein also interacts with ASF1B, we 
conducted pull down assays and examined co-localization of proteins similar to the 
studies with CAF-1A. A S-tag fusion cDNA with ASF1B was created in the pET-30c vector 
and the fusion protein was labeled with [35S]methionine by an in vitro 
transcription/translation system. The expressed fusion protein was purified with S-tag 
agarose beads and incubated with cell lysates containing expressed EGFP fusions of MOZ, 
MOZ-TIF2 and TIF2. Subsequently, EGFP proteins that interacted with ASF1B were 
identified by western blot analysis with an anti-EGFP antibody (Figure 4A). Both EGFP-
MOZ and EGFP-MOZ-TIF2 could be demonstrated to interact with ASF1B. MOZ-TIF2 
appeared to interact more strongly with the percentage of EGFP fusion protein bound to 
ASF1B approximately 240% over the input for MOZ-TIF2 and 70% for MOZ, respectively. 
TIF2 showed no binding to ASF1B. To further identify the ASF1B binding domain in 
MOZ, the GST-tagged ASF1B was incubated with [35S]methionine labeled MOZ-1/313 
and MOZ-488/703 (Figure 4B). The MOZ-488/703 fragment showed stronger binding to 
ASF1B than MOZ-1/313. The percentage of ASF1B bound to the MOZ-1/313 fragment 
represented about 25% of the input while the percentage of ASF1B bound to the MOZ-
488/703 fragment was 150% of the input.  
3.5 The co-localization of MOZ and MOZ-TIF2 with CAF-1A and ASF1B 
To further verify the interaction of MOZ with CAF-1A, we first examined by indirect 
immunohistochemistry the localization of endogenous MOZ and CAF-1A in Hela cells to 
determine if the subcellular distribution was similar by confocal immunofluorescence 
microscopy (Figure 5A). In Hela cells both MOZ and CAF-1A were predominately localized 
in interphase nuclei (Figure 5A-a). As the chromatin condensed in metaphase MOZ 
distributed dominantly in cytoplasm and disassociated from the spindle-chromosome in 
some cells (Figure 5A-b and 5A-c). CAF-1A was observed either to disassociate from (Figure 
5A-b) or bind to spindle-chromosomes (Figure 5A-c). However, cytoplasmic co-localization 
of MOZ and CAF-1A was still seen as detected by the persistence of yellow by confocal 
microscopy. In anaphase, with paired chromosome separation, CAF-1A was still bound to 
the spindle-chromosome but MOZ was fully dissociated (Figure 5A-d) but with persistent 
co-localization of both in the cytoplasm.  To determine if the MOZ-TIF2 fusion protein has 
similar localization as MOZ and co-localized with CAF-1A, HEK293 cells were transfected 
with EGFP-MOZ or EGFP-MOZ-TIF2 and DsRed2-CAF-1A (Figure 5B). Both EGFP-MOZ 
and EGFP-MOZ-TIF2 showed a predominantly nuclear localization in HEK293 cells in 
interphase. However, the, EGFP-MOZ-TIF2 fusion protein appeared in larger aggregates 
compared to the more homogenously distributed MOZ. In the merged image the MOZ co-
localization with CAF-1A appeared stronger than the MOZ-TIF2-CAF-1A co-localization 
(Figure 5B, top panel, merge). To examine the binding of MOZ, MOZ-TIF2, and CAF-1A to 
the interphase chromatin we conducted pre-extraction with Triton-X100 in EGFP-MOZ and 
EGFP-MOZ-TIF2 transfected HEK293 cells (Figure 5C). In the interphase, all three proteins, 
EGFP-MOZ, EGFP-MOZ-TIF2, and CAF-1A showed resistance to pre-extraction and the co-
localization with DAPI-stained DNA. Similarly, the co-localization of EGFP-MOZ-TIF2 with 
ASF1B was shown in transfected HEK293 cells (Figure 6A). Interestingly, EGFP-MOZ-TIF2 
exhibited stronger co-localization with DsRed2-ASF1B than EGFP-MOZ in pre-extracted 
HEK293 cells (Figure 6B, merge).  
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Fig. 5. Subcellular localization of MOZ, MOZ-TIF2, CAF-1A (p150). A. Indirect 
immunofluorescence of MOZ (green) and p150 (red) in HeLa cells at interphase and 
metaphase observed by confocal microscopy with the nuclei stained with Topro-3. B. Con-
focal microscope images were obtained of HEK293 cells co-transfected with EGFP-MOZ and 
DsRed2-p150 or EGFP-MOZ-TIF2 and DsRed2-p150 as detailed in the Materials and 
Methods and nuclei stained with Topro-3. C. HEK293 cells transfected with EGFP-MOZ 
(green) and EGFP-MOZ-TIF2 (green) and stained with anti-p150 antibody after pre-
extraction with Triton-X100. The fluorescent images were obtained at x100 with a Zeiss 
fluorescent microscope.  





EGFP-MOZ         DsRed2-p150           TOPRO-3                   Merge
EGFP-MOZ-TIF2     DsRed2-p150        TOPRO-3                   Merge
MOZ                     p150                    DAPI                        Merge
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Fig. 6. A. Confocal microscope images were obtained of HEK293 cells co-transfected with 
EGFP-MOZ-TIF2 and DsRed2-ASF1B. The nuclei were stained with Topro-3. B. HEK293 
cells were transfected with EGFP-MOZ or EGFP-MOZ-TIF2. 48 hours later, cells were pre-
extracted, fixed, and immune-stained with anti-ASF1B antibody. Fluorescent images were 
photographed at x100 with a Zeiss fluorescent microscope.  
3.6 Altered gene expression profile in U937 cells stably transfected with MOZ-TIF2  
CAF-1 and ASF1, as histone chaperon proteins are essential in maintaining the nucleosome 
structure after DNA replica and in DNA repair. In yeast, CAF-1 and ASF1 are regulators of 
global gene expression (Zabaronick and Tyler, 2005). However, if MOZ and MOZ-TIF2, as 
proteins that associate with CAF-1 and ASF1, affect global gene expression is not known. 
We established stable transfection clones from U937 cells with forced expression of MOZ 
and MOZ-TIF2 and analyzed global gene expression of these cell clones. Compared to the 
expression profile of control cells stably transfected with pcDNA3 vector alone, MT2 caused 
a > 2-fold change in expression with 181 genes increasing and 106 genes decreasing 
expression (p = 0.01). Over expression of wild type MOZ also altered gene expression (>2-
fold increase in 132 genes and >2-fold decrease in 88 genes, p=0.01). In addition, a 
differential gene expression signature was seen between MOZ and MOZ-TIF2 in a Venn 
EGFP-MOZ-TIF2    DsRed2-ASF1B         TOPRO-3                   MergeA
MOZ                         ASF1                      DAPI                    MERGE
MT2                        ASF1                       DAPI                      MERGE
B
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diagram analysis (Figure 7). The signature-expressed genes are 189 with pcDNA3, 84 with 
MOZ, and 427 with MOZ-TIF2, respectively. Further pairwise analysis of differential 
expression of genes between MOZ and MOZ-TIF2 indicated that there 28 genes increasing 
over 2 fold (Table 1) and 34 genes decreasing over 2 fold (Table 2) in MOZ-TIF2 compared 
with that in MOZ. The altered genes between MOZ and MOZ-TIF2 are involved in multiple 
cell functions such as signal transduction, cell response to stimulus, cell cycle, chromosome 
structure, development, and tumor progression. 
 
Ratio p-value Gene Name 
6.41 0.002777
Transcribed locus, weakly similar to XP_537423.2 PREDICTED: 
similar to LINE-1 reverse transcriptase homolog [Canis familiaris 
5.78 0.001076 Malic enzyme 3, NADP(+)-dependent, mitochondrial 
4.8 0.042772 Testis derived transcript (3 LIM domains) 
4.01 0.021676 Bone morphogenetic protein 1 
3.71 0.031657 Interleukin 8 receptor, beta 
3.63 0.012968 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6, 17kDa 
3.09 0.042154 calreticulin 
2.73 0.047444 Actin binding LIM protein 1 
2.55 0.040271 Ribosome binding protein 1 homolog 180kDa (dog) 
2.43 0.016348 vesicle amine transport protein 1 homolog (T. californica) 
2.41 0.004052 Calreticulin 
2.39 0.039279 histone cluster 1, H2bi 
2.37 0.039548 insulin-like growth factor binding protein 2, 36kDa 
2.36 0.012714 Inversin 
2.36 0.048093 PTK2B protein tyrosine kinase 2 beta 
2.29 0.010907 RAP1 interacting factor homolog (yeast) 
2.22 0.00445 CD160 molecule 
2.13 0.042832 Carnitine palmitoyltransferase 1B (muscle) 
2.13 0.010751 PCTAIRE protein kinase 1 
2.12 0.006671 Neutrophil cytosolic factor 4, 40kDa 
2.11 0.039481 neurogranin (protein kinase C substrate, RC3) 
2.1 0.036043
Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein, epsilon polypeptide 
2.09 0.002837 Mediator complex subunit 21 
2.06 0.008281 Insulin-like growth factor binding protein 2, 36kDa 
2.04 0.032872 acylphosphatase 2, muscle type 
2.03 0.006805 FK506 binding protein 1A, 12kDa 
2.02 0.006539 Neurochondrin 
2 0.001062 Syntaxin 5 
Table 1. Up-regulated genes in MOZ-TIF2 vs MOZ. 
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Ratio p-value Gene Name 
14.58 0.034066 Fibroblast growth factor receptor 2 
10.51 0.048971 Transcribed locus 
5.7 0.020122 Spectrin, beta, non-erythrocytic 1 
5.3 0.007972 Sulfotransferase (Sulfokinase) like gene, a putative GS2 like gene 
5.17 0.005226 Defensin, beta 1 
3.92 0.00956 chorionic somatomammotropin hormone-like 1 
3.68 0.002866 elongation factor, RNA polymerase II, 2 
3.64 0.04087 RAP2A, member of RAS oncogene family 
3.57 0.040904 CD2 molecule 
3.57 0.039775 Met proto-oncogene (hepatocyte growth factor receptor) 
3.34 6.34E-05 Adipose differentiation-related protein 
2.99 0.049188 ATPase, Ca++ transporting, plasma membrane 4 
2.61 0.013043 X-ray repair complementing defective repair in Chinese hamster cells 2 
2.49 0.002229 regulatory solute carrier protein, family 1, member 1 
2.47 0.018837 CMP-N-acetylneuraminate monooxygenase) pseudogene 
2.45 0.049139 Angiogenic factor with G patch and FHA domains 1 
2.45 0.026164 SCY1-like 3 (S. cerevisiae) 
2.36 0.003507 spermidine/spermine N1-acetyltransferase 1 
2.34 0.046867 ATPase, class VI, type 11A 
2.27 0.027531 ecotropic viral integration site 2A 
2.22 0.045457 Ubiquitin specific peptidase like 1 
2.21 0.035349 Cyclin-dependent kinase 6 
2.17 0.000434 CDC14 cell division cycle 14 homolog B (S. cerevisiae) 
2.17 0.032088 Kruppel-like factor 10 
2.17 0.049619 Starch binding domain 1 
2.16 0.023854 Homeodomain interacting protein kinase 3 
2.15 0.030337 Ectodermal-neural cortex (with BTB-like domain) 
2.14 0.010869 Angiogenic factor with G patch and FHA domains 1 
2.12 0.049079 Reversion-inducing-cysteine-rich protein with kazal motifs 
2.11 0.042149 suppressor of Ty 3 homolog (S. cerevisiae) 
2.08 0.037371 Nuclear receptor subfamily 1, group D, member 2 
2.08 0.022954 cytochrome P450, family 1, subfamily A, polypeptide 1 
2.06 0.004142 Peroxisomal biogenesis factor 5 
2.06 0.033184 Fem-1 homolog c (C. elegans) 
Table 2. Down-regulated genes in MOZ-TIF2 vs MOZ. 
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Fig. 7. The Venn diagram of signature gene expression among pcDNA3, MOZ, and MOZ-
TIF2. The positive expressed genes were picked up as described in Materials and Methods. 
The number in brackets indicates the signature genes. 
4. Discussion 
In order to gain understanding of the function of the MOZ-TIF2 fusion protein we used the 
yeast two-hybrid system to screen a human bone marrow cDNA library and identified two 
proteins, CAF-1A and ASF1B, that interacted with the MOZ partner of MOZ-TIF2. The CAF-
1A is the largest subunit of CAF-1 which is responsible for bringing histones H3 and H4 to 
newly synthesized DNA to constitute a nucleosome during DNA replication and DNA 
repair (Moggs et al., 2000; Shibahara and Stillman, 1999; Smith and Stillman, 1989). CAF-1 
controls S-phase progression in euchromatic DNA replication (Klapholz et al., 2009). During 
chromatin assembly CAF-1 is localized at the replication loci through the association with 
the proliferation cell nuclear antigen (PCNA), interacting with the N-terminal PCNA 
binding motif in the CAF-1A. CAF-1 has also been shown to have a role in transcription 
regulation and epigenetic control of gene expression by interacting with methyl-CpG 
binding protein and by contributing non-methylation dependent gene silencing (Reese et al., 
2003; Sarraf and Stancheva, 2004; Tchenio et al., 2001). A dominant-negative mutant of CAF-
1A arrests cell cycle in S-phase (Ye et al., 2003). The loss of CAF-1 is lethal in human cells 
and increases the sensitivity of cells to UV and other DNA damaging reagents (Game and 
Kaufman, 1999; Nabatiyan and Krude, 2004). In addition, CAF-1 has been suggested as a 
clinical marker to distinguish quiescent from proliferating cells (Polo et al., 2004). ASF1B, the 
other MOZ-TIF2 interacting protein identified, is one of two human ASF1 proteins and 
participates in chromatin assembly by interacting with the p60 unit of CAF-1 (Mello et al., 
2002). The function of ASF1 overlaps with CAF-1 but contributes mainly to chromatin-
mediated gene silencing (Meijsing and Ehrenhofer-Murray, 2001; Mello et al., 2002; Osada et 
al., 2001). In the process of nucleosome formation during DNA replication, ASF1 synergizes 
functionally with CAF-1 by binding histone H3/H4 and delivers histone H3 and H4 dimers 
to CAF-1 (Tyler et al., 1999; Tyler et al., 2001). As with CAF-1 mutations, mutations in ASF1 
raise the sensitivity of cells to DNA damage (Daganzo et al., 2003; Emili et al., 2001; Le et al., 
1997). In yeast, the absence of ASF1 leads to enhanced genetic instability and sister 
chromatid exchange (Prado et al., 2004). Recent study revealed that the expression of ASF1B, 
like CAF-1A, was proliferation-dependent (Corpet et al., 2011). Both CAF-1 and ASF1 are 
 [ 84 ]
 [ 427 ]
 [ 189 ]
 [ 258 ]
 [ 444 ]
 [ 52 ]
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important in maintaining genetic stability and hence mutations or aberrant expression in 
either may contribute to carcinogenesis. 
Our initial results demonstrated that the MOZ portion of the MOZ-TIF2 fusion protein 
interacted with the human CAF-1A and ASF1B. These associations are consistent with 
previous findings that a MYST family member in yeast, SAS (something about silencing) 
protein, interacts with Cac1, a yeast homologue of human CAF-1A, and yeast ASF1 and that 
the interaction contributed to the silencing of the ribosomal DNA locus (Meijsing and 
Ehrenhofer-Murray, 2001). However, in our experiments with the yeast two-hybrid system, 
the association between the MOZ-1/759 fragment and CAF-1A was stronger than the 
interaction of the MOZ-1/759 fragment and ASF1B. The clones of MOZ-1/759 and CAF-1A 
grew in both –His and –Ade selection media while the clones of MOZ-1/759 and ASF1B 
grew only in the –His medium. These results suggest that the intensity of interaction of the 
MOZ fragment with each chaperone is different and the interactions may involve different 
domains of MOZ. With the GST pull-down assays, we were able to verify the physical 
interactions using purified proteins and to begin probing the regions of MOZ involved in 
the interactions.  Our results demonstrated that CAF-1A bound primarily to the N-terminus 
of MOZ (MOZ-1/313) while ASF1B bound to the domain containing C2HC motif and 
acetyl-CoA binding region (MOZ-488/703). To exclude possible indirect interactions caused 
by using a mammalian transcription/ translation system, the pull-down assay was also 
conducted using an E. coli translation system (EcoProTM T7 System, EMD Biosciences, 
Novagen, San Diego, CA) with the same interactions being seen again (data not shown). The 
binding of CAF-1A and ASF1B to two distinct regions within the MOZ fragment involved in 
the MOZ-TIF2 fusion protein suggests that MOZ-TIF2 positively influences participation in 
chromatin assembly.   
The experiments reported here also begin to shed some light on aberrant function of the 
MOZ-TIF2 fusion protein by comparing semi-quantatively the strength of association of 
CAF-1A and ASF1B with MOZ and MOZ-TIF2. In the co-immunopreciptiation and S-tagged 
pull down experiments, CAF-1A appeared to interact more strongly with MOZ than MOZ-
TIF2. These observations were confirmed by the increased co-localization seen in confocal 
microscopy of the co-transfected cells at interphase. The converse was seen in the 
interactions of ASF1B with an apparent greater intensity of interaction of ASF1B with MOZ-
TIF2 than MOZ alone. Again, this interaction was confirmed in pre-extracted HEK293 cells. 
It seems that MOZ-TIF2 fusion protein changed the binding priorities of MOZ. These 
differences may occur because of the necessity of appropriate folding or other higher order 
structural changes in the full-length MOZ, which are obviated in the fusion protein. In 
addition, we noticed that the localization of MOZ and CAF-1A was altered in mitotic cells, 
suggesting that the function of interactions in chromatin assembly and modification depend 
on cell division cycle. Previously, CAF-1 has been observed to disassociate from 
chromosomes during the M phase and to be inactivated in mitosis (Marheineke and Krude, 
1998). However, we have seen the binding of CAF-1A to the spindle-like chromosome 
during the metaphase and anaphase in immune-stained Hela cells. It is not clear if the 
altered association of CAF-1A with chromosome indicates a physiological process during 
the mitosis or is the artificial results either of fixation and stain process or the limitation of 
the antibody. A further investigation is necessary to determine the dynamic change of the 
association. 
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Using stably transfected U937 cells, we were able to find MOZ-TIF2-correlated changes in 
the global expression profile of genes and identify a signature-expression profile for MOZ-
TIF2.  However, as MOZ and TIF2 function as transcription co-factors and as CAF-1 and 
ASF1 are regulators of global transcription the altered gene expression by MOZ-TIF2 cannot 
be ascribed to the interaction of MOZ-TIF2 with CAF-1A and ASF1B alone. Interestingly, 
inspite of 427 expressed signature genes of MOZ-TIF2, only 62 genes were found with over 
two-fold significant change between MOZ-TIF2 and MOZ, suggesting that differences in 
expression level between MOZ and MOZ-TIF2 of most most signature genes signature 
genes could be relatively small.  
We are currently examining the hypothesis that the association of MOZ-TIF2 with 
chromatin assembly factors affects the nucleosome structure and/or histone modification 
such that histone acetylation status would contribute to leukemogenesis. This hypothesis 
assumes that the MOZ-TIF2 fusion protein may alter constitution of the chromatin assembly 
factor complex and then change global gene expression. A possible target for this type of 
altered function would be that the fusion protein could alter the recruitment of CBP to the 
complex via LXXLL motifs in TIF2 portion (Voegel et al., 1998; Yin et al., 2007).  
5. Conclusions 
We demonstrate that both MOZ and MOZ-TIF2 interacts with ASF1B via its MYST domain 
and interacts with CAF-1A via its zinc finger domain. MOZ and MOZ–TIF2 co-localize with 
CAF-1A and ASF1B in interphase nuclei. MOZ-TIF2, compared to MOZ, preferentially 
binds to ASF1B rather than to CAF-1A. MOZ-TIF2 interferes with the function of wild type 
MOZ and alters global gene expression in U937 cells. 
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cellular activity, but also leads to potential agents for the treatment of various diseases. The objective of this
book is to highlight some of the latest approaches in the study of protein interactions, including modulation of
protein interactions, development of analytical techniques, etc. Collectively they demonstrate the importance
and the possibility for the further investigation and modulation of protein interactions as technology is evolving.
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